Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Antibody Becomes First Home-Grown COVID-19 Drug Approval In Korea

Executive Summary

Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.

You may also be interested in...



Celltrion Sees Double-Digit Growth In Sales And Profit

South Korea’s Celltrion saw a double-digit jump in sales and operating profit in 2020 based on continued growth for its leading biosimilars. Meanwhile, the company is pursuing its strategy of developing at least one biosimilar annually.

Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning

Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic. 

Celltrion Expands In APAC, Small Molecules Via $278m Takeda Asset Buy

In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel